Dan Horsey

Dan Horsey

Dan joins the Marketing team at Medable. Previously, Dan was a Content Manager at Signant Health and a Marketing Manager at IQVIA. He got his start in healthcare marketing in 2014, working with Pharmacy Benefits Managers in the managed Medicare and Medicaid spaces, and has been writing in healthcare capacities for over 10 years. Dan has extensive experience in creating both long and short forms of content across a wide variety of mediums. He earned his Bachelor of Arts in Communications from West Chester University in 2009. In his spare time, Dan composes music as a hobby and plays guitar for a Philadelphia based hardcore band.

Recent posts by Dan Horsey

3 min read

Together We Can: Why our Mission for More Inclusive Research Needs You

By Dan Horsey on Aug 17, 2021 4:05:28 PM

At Medable, our vision is to open scientific research to the world.

Why?

Because for decades, access to clinical trials has been limited to significantly fewer biologies and human bodies than that of our world’s populations. This limited access to clinical trials has had a direct impact on the development of new medicines, which has remained slow, cost-intensive, and poorly reflective of disease-affected and world populations¹.

Today, our industry understands that differences in race, geography, gender, and many other factors may often have an impact on the efficacy of our treatments. Certain oncology, albuterol, and cardiac medications have been proven to be less effective for minority populations than for their Caucasian counterparts. This difference in effectiveness starts with clinical trial representation. Unfortunately, the FDA’s 2018 Drug Trials Snapshot report showcases this disparity is still very real. Of those who participated in Oncology trials in 2018, only 38% of participants were women, 15% were Asian, 4% were African American, and 4% were Hispanic. 

Thankfully, the recent convergence of science and technology has given our industry a prime opportunity to correct this disparity in the form of decentralized clinical trials. 

When Medable was created in 2014 we set out to make research ubiquitous for everyone using a decentralized clinical trial platform designed for every body, and every biology. As it stands today, decentralized clinical trials offer the life sciences industry the best possible path towards a future where trials are faster, more efficient, less costly, and most importantly, inclusive of everyone.

With Informa Pharma Intelligence reporting that 76% of companies are expanding their decentralized clinical trial capabilities, organizations worldwide are revamping their research and development engines, adding decentralized capabilities to their traditional suite of services.

It’s with these efforts in mind, that we have developed an industry-first training program designed to provide workforces everywhere with the specialized tools, knowledge, and skills necessary to develop and rapidly scale decentralized and hybrid trials. 

Within our industry, expertise has consistently proven itself a key driver of innovation. While Medable’s mission and vision have been executed across more than 150 decentralized trials, it’s not enough. In order to make medicine more effective, less costly, and more inclusive, we need you.

Together, we can help guide and share our scientific development model, furthering our vision of opening scientific research to the entire world. 

Together, we can help build new paths, develop new roles, and create new learnings that will empower the industry to design, build, deploy and support decentralized and hybrid trials.

Together,  we can scale best practices and shared expertise to help trial teams break down traditional barriers, reduce cycle times, enhance data quality, and improve patient access and experience. 

And together, we can help create and scale a more inclusive science. Because medicines used by every body, require every biology. 

References

¹When will clinical trials finally reflect diversity? Nature 557, 157-159 (2018)

https://doi.org/10.1038/d41586-018-05049-5 

Clinical Trial Diversification, Better Practices

http://www.transceleratebiopharmainc.com/wp-content/uploads/2015/07/Clinical-Trial-Diversification-Better-Pracitces-1a-Diversity-Awareness-for-Sponsors-vPresentation.pdf 

Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial Participation

https://academic.oup.com/jnci/article/111/3/245/5307078 

Digitizing clinical trials.

https://doi.org/10.1038/s41746-020-0302-y

The Impact of Protocol Amendments on Clinical Trial Performance and Cost

https://doi.org/10.1177/2168479016632271 

Accelerating Adoption of Patient-Facing Technologies in Clinical Trials: A Pharmaceutical Industry Perspective on Opportunities and Challenges

https://link.springer.com/article/10.1177/2168479018801566 

Topics: decentralized trials PatientCare Innovation clinical trials Inclusion
3 min read

Medable Celebrates Being Named the Leader in the Everest Group Report by Exploring "The Why?"

By Dan Horsey on Aug 6, 2021 9:48:20 AM

On Friday, July 16, 2021, Medable was recognized as the Leader in Decentralized Clinical Trial Products, according to Everest Group’s DCT Product PEAK Matrix Assessment 2021

For those who may not know, The Everest Group’s PEAK Matrix is an independent, objective, data-driven assessment of key service and technology providers based on overall capability and market impact. Thus, it’s an honor that Medable was positioned highest in the Leaders quadrant with top scores for both vision and capability as well as market impact. 

While being named a leader is important, it pales in comparison to the effect that our hard work has in creating a more inclusive, equitable future for medicine. That’s because each consent delivered, diary completed, and televist made helps further the adoption of a future where treatments and health outcomes are developed for everyone. 

With this mission and award in mind, we took the time to ask our employees the following pivotal questions:

  • Why did you decide to work in clinical trials?
  • What’s your hope for the future of clinical trials?
  • And why Medable?

Their answers are an affirmation to our mission, our organization and our future. 

Why did you decide to work in the clinical trial industry?

  • To play a small part in improving human health.
  • Research needs human-centered design. Science wants controlled environments; the real world is messy. If we are user-focused, we can collect data with a wide range of participants and empower their experience to glean even deeper insights.
  • My family members are diagnosed with LVNC. With this disease, there is no path for care for my family, my children, and myself. I can't accept this. I made it my mission to be a part of technology to change clinical trials for others to ensure we solve what we are fighting for.
  • I like to contribute to making the world a better place, and I believe research is one very powerful way to do that. Research creates preventative medicine for people on a global scale. To me, that’s invaluable.
  • Because I myself am bipolar type II, and my mental health has been greatly improved by commercial drugs.

 What’s your hope for the future of trials?

  • That we build trust and awareness across society, around what clinical research entails and why it’s necessary, by allowing individuals to be empowered with their own health data and to donate it where and when it’s needed.
  • That participation in trials becomes less burdensome and more accessible for people around the globe.
  • My hope is for treatments to undergo a more efficient and quicker drug development cycle - from discovery to approval. Allowing those drugs (that have promising results) to reach their intended patient population quicker is something we should be striving for. I've got several family members living with chronic illnesses and being able to reduce this cycle time would have a direct impact on their quality of life and/or even prolong their health.
  • To expand clinical research access to any patient who is interested in participating.
    A future where patient preferences are incorporated early and often.
  • I hope that clinical research can encompass all of the diversity in the world so that treatments can be developed that are effective in all populations.

Why Medable?

  • Medable helps patients join in clinical trials without having to travel. This has the potential to expand trial participation into rural areas and previously underserved populations that are currently underrepresented.
  • Because it's accelerating drug therapies to market and expanding clinical research access to populations that would have otherwise gone unrepresented.
  • Patient-centric approach - not only talking the talk but walking the walk. Everything is focused on reducing the burden, with quality built-in while also driving the diversity of patient populations.
  • We are making healthcare more engaging, consumer-friendly, & accessible, which will ultimately lead to higher quality medications.
  • The elements of decentralized clinical study design that Medable can deliver has a positive impact on the cost of medicine and the throughput of clinical research while embracing patient-centricity and diversity.
  • Patient centricity and access to clinical studies will have a massive impact on how studies will be undertaken in the future.

If you'd like to join Team Medable, view our open positions here: https://www.medable.com/company/careers 

Topics: medable clinical trials Decentralized Diversity
2 min read

Medable is The Leader in DCTs

By Dan Horsey on Aug 4, 2021 1:03:03 PM

On Friday, July 16 2021, we were honored to learn that The Everest Group named Medable as the Number One Leader in Decentralized Clinical Trial Products.

The Everest Group is a prestigious “firm focused exclusively on IT, business process, and engineering services.” The firm helps industry leaders gain a “depth of expertise that our clients find invaluable when making critical, strategic decisions related to their use and delivery of sourcing services.” 

Their PEAK Matrix is an independent, objective, data-driven assessment of key service and technology providers based on overall capability and market impact. Thus, we’re humbled that Medable was positioned highest in the leaders quadrant with top scores for both vision and capability as well as market impact. 

The group ranked Medable alongside 14 other companies that specialize in providing decentralized clinical trials. With the recent rise of decentralized clinical trials (DCTs) the market has experienced rapid growth, with hundreds of companies now expanding their capabilities to adjust for the industry’s seismic shift towards patient-centric trials. 

Medable was selected as the leader as a result of our market impact, as well as our vision and capabilities. As the leader in DCT, our company stands out based on five key factors: 

  1. A comprehensive suite of decentralized product capabilities including: eConsent, wearables, BYOD, RPM, medication adherence, televisit, and eCOA/ePRO.
  2. A flexible and extensible platform that supports DCT workflows such as: screening, recruitment, home health and patient engagement.
  3. DCT system that effortlessly scales and integrates with any eClinical platform.
  4. Expertise in human-centered design to enable faster cures and better patient outcomes.
  5. Motivated by the vision and mission of a company founded and run by a physician.

While we’re honored to be ranked number one among our peers, we’re more excited about what it means for our mission of making clinical research more accessible and inclusive for the world’s populations. 

If you’re curious as to what Medable can do for your trials, click here to set up some one-on-one time with a Medable DCT subject matter expert. 

If you would like to access the full report from The Everest Group: click here.

Topics: medable DCT PatientCare Health Care clinical trials Decentralized
2 min read

Highlights From Scope 2021, and the Clinical Trial Road Ahead

By Dan Horsey on Mar 17, 2021 12:44:02 PM

Those in the clinical trial industry understand that there are several barometers that can be used to gauge the overall state of the industry. Chief among these are the “big conferences” that occur each year, such as  SCOPE, J.P. Morgan week, and D.I.A.  

With another SCOPE behind us, we thought we’d take the time to summarize what we felt were some of the important industry trends and topics discussed in detail this year. 

 

An Increased Focus on Sensors in Trials

With the outside world still continuing to keep the majority of patients at home, a large focus at this year’s scope was on the promise and potential of sensors and wearables in the market. 

New ideas about the best ways to capture and use clinical trial data were bolstered by arguments showing the positive impact to drug development that comes from combining trial data with supplementary patient data. While the overall sentiment was positive and hopeful around the growing use of sensors, many cautioned that there would need to be a large concerted effort to centralize their deployment and standards of use with review boards and regulators worldwide. 

Presentation(s) of Note: 

Sensors and Wearables in a Decentralized World - Play back available now.
Ali Holland,Exec GM, Digital and Decentralized Solutions

Meeting all Endpoint Needs with a Single Platform
Geoff Gill, President, Shimmer Americas, Shimmer Research

 

The Growing World of Decentralized and Remote Trials

Continuing the sentiments of 2020, decentralization and remote trials continued to influence the conference at large. Many industry organizations touted their plans and capabilities when it came to administering trials at home, in-office, or anywhere in between. 

Furthermore, more companies were speaking to the general needs and circumstances that have led us towards decentralization. This includes not only COVID-19, but older research indicating how many patients, sites, and even sponsors are burdened and constrained by in-clinic only trials. 

Presentation(s) of Note: 

Scaling Decentralized Trials: Best Practices and Lessons Learned to Help Strengthen Patient-Centricity & Trial Delivery
Nagaraja (Sri) Srivatsan, Senior Vice President and Chief Digital Officer, Technology Solutions, IQVIA
Christopher Varner, Associate Director, Virtual Trials, IQVIA

 

The Effect of COVID-19 on Our Industry

For those who didn’t see this one coming, it only took a brief glance at this year’s agenda to know what would be a major talking point at this year’s SCOPE.

COVID-19 drove discussions pertaining to topics relevant across our entire industry. This included COVID as a driver for innovation, but also flexibility, speed, new ways of running trials, changing regulations, and the lasting legacy of clinical trials. 

Presentations of note:

Keynote Presentation: COVID-19: How an External Event Redoubled Janssen’s Culture of Innovation
Darren Weston, Vice President, Integrated Data Analytics & Reporting (IDAR), Janssen

 

Overall

As one could expect, several of the main themes of this year’s SCOPE were a direct result of our world in 2020. What SCOPE cemented, however, was that the “new norm” of doing things, one brought upon by COVID, is definitely here to stay.

3 min read

Recap: Industry Experts Discuss the Current and Future State of DCT - Insights from HCL Technologies' "Straight Talk" Session

By Dan Horsey on Mar 3, 2021 10:42:00 AM

On Thursday, February 24th, eight healthcare professionals from a coalition of clinical trial companies gathered on Twitter. Together, they were led through a series of questions about the impact, future, and value of decentralized clinical trials (DCTs) by HCL Technologies. 

Medable’s own Tyler Pugsley was one of eight professionals, answering questions from HCL and the live audience together in a new Twitter series known as “Straight Talk.” The blog below serves as a recap of key insights from their discussion.

Question 1 - How big a role will virtual/decentralized clinical trials play in future pharma R&D?

The group stated that virtual trials are here to stay now, having made a foothold in the industry prior to 2020, and becoming mainstream as a direct result of COVID. Thus, they will continue to play a vital role in the future of trials. 

When it came to discussing the role they will continue to play, many stated that DCT has a directly positive impact on trial access, as they expand the patient population pools out of specific geographic regions, and into the national level. Others discussed the benefits of passive data, and it’s combination with TeleHealth. Used appropriately, each has the ability to provide a clearer picture of a patient, their health, and how they’re progressing through a trial.

Finally, some highlighted the added benefits of speed, and reduced costs that come with the embrace and proliferation of services like TeleHealth, direct to patient labs, and more.

Question 2 - In what ways is the technology to support such clinical trials (DCTs) evolving?

The panel noted that technology is often a tool for removing barriers and improving communication with current solutions making trials more patient-centric, and opening access to anytime, anywhere clinical trial participation.

For instance, wearables have evolved to become smaller, less cumbersome, and better at passive data collection during the last few years. Other technologies have focused on closing the gaps between clinicians and patients, with real-time data helping clinicians understand how to facilitate ongoing patient engagement and manage health conditions.

Medable’s Tyler Puglsey, VP of Business Development and Growth laid out his vision for the future, as he believes the way we perceive patients will change over time to see them more as consumers of trials, and less participants.

Question 3 - How has COVID-19 changed the industry’s approach to adopting virtual/decentralized clinical trial platforms, instead of more traditional electronic data collection platforms (EDC)?

Here, many were quick to point out that COVID-19 seemed to remove many of the barriers towards DCT adoption almost overnight, noting that the pandemic highlighted what the industry could have looked like for some time.

Additionally, participants responded with the real world concerns brought on by the pandemic, noting that patients were unwilling to go onsite in many instances. The result? Televists, remote monitoring and more have become the “new normal” for many studies, as they provide an effective and safe way to interact with patients.

Question 4 - How can an organization transition to decentralized clinical trials at enterprise scale across its entire clinical research portfolio.

With this question, one panelist noted that the true barrier that must be overcome for enterprise scaling is culture. Focusing on technology alone, others suggested organizations begin by leaning into key components of DCT, such as online eConsent and eCOA that would allow for greater digital data collection.

Finally, some noted that these processes must be directly integrated into both the organization’s infrastructure and key processes in order to see the true benefits of data, workflow, and speed.

Question 5 - What long-term effect will such clinical trials (DCTs) have on drug development?

Many panelists noted that patient centered designs met with technology that increases convenience and mobility are here to stay. While many saw long-term gains in improving patient recruitment, engagement, and trial data. 

Others hoped to see the downfall of trial failure due to patient recruitment and dropout issues. 

With perhaps the clearest take on the industry’s future, our own Tyler Pugsley cut straight to the core of the issue, stating that “Let's break it down to the core objective: Speed to safe and effective drug approvals.”



2 min read

The First Step is Education: Medable’s Jennifer McNary nominated by Reuters for Her Work in Rare Disease Advocacy

By Dan Horsey on Dec 21, 2020 10:31:17 AM

“The reason the Master Class is happening is because advocates like myself were not given a roadmap when our children were diagnosed with rare diseases,” states Jennifer McNary, Rare Disease Advocate. She’s flanked virtually, by her peers and fellow patient advocates for Reuter’s Events 2020 Pharma awards.

Jennifer, alongside three other nominees, is being honored for her work in furthering patient advocacy. Jennifer supports the Patients Rising Master Class she mentions as a faculty member, which is facilitated by fellow Reuters nominee, Lilly Stairs, and is simply a part of her everyday work in furthering the education that exists for patients who suddenly find themselves at the tail end of a rare disease diagnosis.

For Jennifer, and many advocates like her, proper education is the first step in creating a roadmap towards treatment. “Really, the key is that when you have success, instead of keeping that to yourself, share it.”

Thankfully, Jennifer has been instrumental in creating roadmaps for rare diseases for years, most notably with Duchenne Muscular Dystrophy (DMD).  In fact, her work as the Director of Outreach and Advocacy at a Massachusetts based non-profit foundation is the reason for what was the largest FDA advisory committee hearing in history for DMD.

pasted image 0

Jennifer’s end goal? Better access to treatment and greater speed to cures.

“Approved doesn’t mean accessible,” Jennifer says. “There are so many disparities around who can participate in a trial. When my son was in a trial we were flying back and forth across the country every week for blood work.”

Thankfully, Jennifer acknowledges that those days are starting to change. Companies across the globe, such as Medable, where Jennifer chairs the Patient Advisory Council for 2020, are helping to bridge the gap between patients and trials. Home measurements, remote assessments and other technologies greatly increase access to trials that were previously only available to a select few.

Recently, advancements in DMD treatment have given advocates like her hope.  Yet, she acknowledges there is still much work to be done, not only in DMD, but in rare diseases with little to no treatment plans.  

“My hope for all the rare disease community is that we continue enhance flexibility at companies like ours, enhance education, and be prepared to provide access and reimbursement for these kinds of therapies,” Jennifer notes, “So that when someone is born with a rare disease in five years there’s a pre-established treatment plan to help them.”

To learn more about the Master Class, please visit the Patients Rising Now website here

 

About Jenn:

Jenn McNary is a trusted voice in the rare disease community, as a mother, public speaker and fierce advocate. Her work in the rare disease space as a thought leader earned her the Ryan’s Quest Ryan’s Hero award in 2013, a nomination for the Global Genes Champion of Hope award in 2014, and the prestigious 2017 Meyer- Whalley instrument of change award. Formerly as the director of outreach and advocacy at a Massachusetts based non-profit foundation, she was responsible for the organization of the largest FDA advisory committee hearing in history, with over 1000 Duchenne Muscular Dystrophy (DMD) advocates, families, clinicians and researchers in attendance.

Topics: life sciences DMD rare diseases
2 min read

Medable named “Life Sciences Innovation Champion” in the 2020 Accenture HealthTech Innovation Challenge

By Dan Horsey on Dec 17, 2020 12:48:07 PM

Medable is proud to announce we have been named “Life Sciences Innovation Champion” in the 2020 Accenture HealthTech Innovation Challenge. Accenture has recognized Innovation Champions since 2016, by inviting healthtech startups across the globe to demonstrate how they can bridge the gap between startups and life science companies to put innovation at the heart of their business and patents. This year, they invited life science startups to showcase their businesses and answer:

“How can we transform the patient experience prior, during or after care (at-home, outside of clinics)?”

Accenture selected Medable as Life Sciences Innovation Champion for the 2020 Accenture HealthTech Innovation Challenge for providing patients with an integrated digital and physical experience during clinical trials, allowing them to access clinical care sites and clinical trial teams from their mobile phones.

At Medable, we believe that healthcare works best when it’s designed to improve the lives of patients everywhere. Thus, we’re excited, humbled, and grateful to be recognized as a leading company that’s working to simplify clinical trials through decentralization, while providing greater access to patients across the globe. 

Our own Tyler Pugsley, VP of Life Science at Medable expresses our commitment to improving the clinical trial experience:

“We are extremely honored to receive this recognition from the Accenture HealthTech Innovation Challenge. Clinical innovation is only possible through the great contributions of patients. This recognition from Accenture allows us to further improve the patient experience so that any person, anywhere, can participate in a clinical trial.”

1517353380697-1

The Accenture HealthTech Innovation Challenge also showcases the breadth of advances happening every day across the life science ecosystem and recognizes more than just the hard work of Medable. It also honors the work of every startup in life sciences and the greater healthcare industry who has brought and inventive patient solutions to our market. This is especially true in 2020, as the industry works tirelessly to react and adapt to a world faced with new challenges and adversity as a direct result of the COVID-19 pandemic.

We’re also proud that so many of our peers have taken new and novel approaches towards solving the issues that continue to afflict our industry. So, if you have a moment, please take a second to recognize the following companies!

  • Cardiolyse, a cloud electrocardiogram (ECG) & heart rate variability (HRV) analytics platform that enables real-time remote heart health monitoring, providing plain-language personalized reports, detection and up to two months data-based prognosis on dangerous heart events;
  • Donisi, a global company at the forefront of contact-free health monitoring that works to change lives without changing lifestyles;
  • Particle Health, which is helping healthcare companies by offering simple, secure access to vital medical data by breaking down data silos that stunt innovation; and
  • Sidekick Health, which operates a patient-centric digital care platform driven by gamification and is scalable across a wide range of chronic illnesses.
Topics: decentralized trials DCT life sciences Innovation